Agreement of Nanolek LLC with Bilthoven Biologicals (Netherlands) on inactivated polio vaccine« Назад
Russian drugmaker Nanolek and Dutch vaccines producer Bilthoven Biologicals, which was acquired by Serum Institute of India in 2012, have officially commissioned a new plant for the production of vaccines in the Russian Kirov region, reports The Pharma Letter’s local correspondent.
According to plans of the partners, at the initial stage they will focus on the production of Russia’s first vaccine against poliomyelitis. That means that already next year the volume of production of the vaccine will amount to 2 million doses of a total demand of more than 3.5 million doses per year.In the long-term the production will be increased up to 10 million doses per year.
According to Vladimir Khristenko, president of Nanolek, a joint venture between RusNano with Russian biotechnology company Epidbiomed,the new vaccine will be by 10%-30% cheaper than its foreign analogues, which will help it to successfully compete with them in the domestic market.
Mr Khristenko added that the new vaccine will be supplied both to the domestic and foreign market, and in particular for the needs of the World Health Organization (WHO) and the UN Children's Fund (UNICEF).
The launch of the new production facility is part of the recently announced ambitious plans of Nanolek for a significant increase of its production capacities in the coming years from the current 1.5 billion to 4 billion tablets. As part of these plans, the company is considering implementing a number of partnership projects with some global pharma majors, among which are Sanofi Pasteur, Merck, Aspen, Egis, Celltrion and Teva, which involves the establishment of contract manufacturing of their drugs at the facilities of Nanolek.